

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Michael B. Fowler, M.B., F.R.C.P.	POSITION TITLE		
eRA COMMONS USER NAME	Professor of Medicine		
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Charing Cross Medical School, London	M.B., B.S.	1975	Medicine
Charing Cross Medical School, London	M.R.C.P., I	1977	Medicine
Charing Cross Medical School, London	M.R.C.P., II	1978	Medicine
Charing Cross Medical School, London	F.A.C.C.	1988	Medicine

**A. Positions and Honors****Positions and Employment**

2001- Medical Director, Cardiomyopathy Center, Stanford University Medical Center, Stanford, CA  
 2001- Director, Heart Failure Program, Stanford University Medical Center, Stanford, CA  
 1999- Professor of Medicine, Cardiovascular Medicine, Stanford Medical Center, Stanford, CA  
 1993-1999 Assoc. Prof. of Medicine, Cardiovascular Medicine, Stanford Medical Center, Stanford, CA  
 1991-2001 Co-Director, Heart Failure Clinic, Stanford University Medical Center, Stanford, CA  
 1986-1993 Asst. Professor of Medicine, Cardiovascular Medicine, Stanford Medical Center, Stanford, CA  
 1986-1991 Co-Director, Coronary Care Unit, Stanford University Medical Center, Stanford, CA  
 1984-1991 Co-Director, Cardiac Advanced Therapies Clinic, Stanford Medical Center, Stanford, CA  
 1984-1986 Clinical Asst. Prof. of Medicine, Cardiology Division, Stanford Medical Center, Stanford, CA

**Awards and Honors**

1982 - 1984 British/American Reciprocal Fellowship Award of the British Heart Foundation & American Heart Association.

**Professional Memberships**

American College of Cardiology (Fellow)  
 American Federation for Clinical Research  
 American Heart Association  
 American Heart Association/California Affiliate  
 American Heart Association Council on Clinical Cardiology  
 American Heart Association/American College of Cardiology Committee to Develop Guidelines for Management of Congestive Heart Failure  
 American Society of Hypertension  
 British Medical Association  
 International Society for Heart Transplantation  
 Royal College of Physicians  
 Heart Failure Society of America  
 The California Academy of Medicine  
 British Cardiac Society  
 European Society of Cardiology  
 International Society of Cardiovascular Pharmacotherapy  
 European Society of Cardiology, Working Group on Heart Failure

**B. Selected peer-reviewed publications** (publications selected from over 230 peer-reviewed publications)

1. Krum H, Mohacsi P, Katus HA, Tendera M, Rouleau JL, **Fowler MB**, Coats AJ, Roecker EB, Packer M; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. *Am Heart J.* 2006 Jan;151(1):55-61.
2. Witteles RM, **Fowler MB**. Cardiomyopathy of insulin resistance. *Heart Fail Clin.* 2006 Jan;2(1):13-23
3. Bell DS, Lukas MA, Holdbrook FK, **Fowler MB**. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. *Curr Med Res Opin.* 2006 Feb;22(2):287-96.
4. Greenberg B, Lottes SR, Nelson JJ, Lukas MA, **Fowler MB**, Massie BM, Abraham WT, Gilbert EM, Franciosa JA, COHERE Participant Physicians. Predictors of clinical outcomes in patients given carvedilol for heart failure. *Am J Cardiol.* 2006 Dec 1;98(11):1480-4. Epub 2006 Oct 12.
5. Francois JA, Nelson MA, Lottes SR, Massie BM, **Fowler MB**, Greenberg B, Gilbert EM, Abraham WT. Heart Failure in Community Practice: relationship to age and sex in a beta-blocker registry. *Congestive Heart Failure* 2006 Nov-Dec; 12(6): 317-23.
6. DeGoma EM, Vagelos RH, **Fowler MB**, Ashley EA. Emerging therapies for the management of decompensated heart failure: from bench to bedside. *J Am Coll Cardiol.* 2006 Dec 19;48(12):2397-409.
7. Abraham WT, Massie BM, Lukas MA, Lottes SR, Nelson JJ, **Fowler, MB**, Greenberg B, Gilbert EM, Franciosa JA, COHERE Participant Physicians. Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry. *Congest Heart Fail.* 2007 Jan-Feb; 13(1):16-21.
8. B. Massie, J. Nelson, M. Lukas, B. Greenberg, **M. Fowler**, E. Gilbert, W. Abraham, S. Lottes, J. Franciosa Comparison of Outcomes and Usefulness of Carvedilol Across a Spectrum of Left Ventricular Ejection Fractions in Patients With Heart Failure in Clinical Practice. *Am J Cardiol.* 2007 May 1;99(9):1263-8.
9. **M. Fowler**, S. Lottes, J. Nelson, M. Lukas, E. Gilbert, B. Greenberg, B. Massie, W. Abraham, J. Franciosa  $\beta$ -Blocker dosing in community-based treatment of heart failure. *Am Heart J.* 2007 Jun;153(6):1029-36.
10. Angela Tsiperfal, MS, RN; Kimberly Scheibly, MS, RN; **Michael B. Fowler, MB, FRCP**; Cara Chao, RN, MS. Why do we need to prevent right ventricular pacing? *Prog Cardiovasc Nurs.* 2007 Spring;22(2):108-9.
11. Witteles RM, Kao D, Christopherson D, Matsuda K, Vagelos RH, Schreiber D, **Fowler MB**. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. *J Am Coll Cardiol.* 2007 Nov 6;50(19):1835-40.
12. Witteles RM, **Fowler MB**. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. *J Am Coll Cardiol.* 2008 Jan 15;51(2):93-102.
13. **Fowler MB**. Hypertension, heart failure, and beta-adrenergic blocking drugs. *J Am Coll Cardiol.* 2008 Sep 23;52(13):1062-72.

14. Kuppahally SS, **Fowler MB**, Vagelos R, Wang P, Al-Ahmad A, Paloma A, Liang D. Worsening of Left Ventricular End-Systolic Volume and Mitral Regurgitation without Increase in Left Ventricular Dyssynchrony on Acute Interruption of Cardiac Resynchronization Therapy. *Echocardiography*. 2009 Jun 17.

### **C. Research Support**

#### **Ongoing Research Support**

**Project Period:** 6/14/08 – 6/13/10

**Sponsor:** Corventis, Inc.

**Role:** PI

**Title:** Multi-Sensor Monitoring in Congestive Heart Failure Study (MUSIC)

**Project Period:** 12/19/07 – 12/31/09

**Sponsor:** Merck

**Role:** PI

**Title:** Effect of Sitagliptin on Insulin Resistance and Myocardial Metabolism in Heart Failure

**Project Period:** 12/10/08 – 11/30/09

**Sponsor:** Investigator Initiated

**Role:** PI

**Title:** Trimetazidine for Insulin Resistant or Diabetic Patients with Non-ischemic Dilated Cardiomyopathy